HomeCompareREVRQ vs PFE

REVRQ vs PFE: Dividend Comparison 2026

REVRQ yields 238.57% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REVRQ wins by $343.79M in total portfolio value
10 years
REVRQ
REVRQ
● Live price
238.57%
Share price
$0.07
Annual div
$0.17
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$343.84M
Annual income
$188,449,047.57
Full REVRQ calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — REVRQ vs PFE

📍 REVRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREVRQPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REVRQ + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REVRQ pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REVRQ
Annual income on $10K today (after 15% tax)
$20,278.57/yr
After 10yr DRIP, annual income (after tax)
$160,181,690.43/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, REVRQ beats the other by $160,159,370.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REVRQ + PFE for your $10,000?

REVRQ: 50%PFE: 50%
100% PFE50/50100% REVRQ
Portfolio after 10yr
$171.94M
Annual income
$94,237,653.15/yr
Blended yield
54.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

REVRQ
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-1.1
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REVRQ buys
0
PFE buys
0
No recent congressional trades found for REVRQ or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREVRQPFE
Forward yield238.57%6.13%
Annual dividend / share$0.17$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$343.84M$49.6K
Annual income after 10y$188,449,047.57$26,258.71
Total dividends collected$326.97M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: REVRQ vs PFE ($10,000, DRIP)

YearREVRQ PortfolioREVRQ Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$34,557$23,857.14$9,153$693.39+$25.4KREVRQ
2$114,026$77,049.97$8,593$849.25+$105.4KREVRQ
3$359,613$237,604.79$8,336$1,066.78+$351.3KREVRQ
4$1,085,115$700,329.09$8,437$1,384.80+$1.08MREVRQ
5$3,136,036$1,974,963.04$9,013$1,875.40+$3.13MREVRQ
6$8,689,897$5,334,338.27$10,306$2,680.72+$8.68MREVRQ
7$23,112,537$13,814,347.36$12,820$4,101.38+$23.10MREVRQ
8$59,068,778$34,338,364.07$17,673$6,826.70+$59.05MREVRQ
9$145,221,031$82,017,437.90$27,543$12,591.86+$145.19MREVRQ
10$343,835,550$188,449,047.57$49,560$26,258.71+$343.79MREVRQ

REVRQ vs PFE: Complete Analysis 2026

REVRQStock

Revlon, Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells beauty and personal care products worldwide. The company's Relvon segment offers color cosmetics and beauty tools under the Revlon brand; and hair color under the Revlon ColorSilk and Revlon Professional brands. Its Elizabeth Arden segment markets, distributes, and sells skin care products under the Elizabeth Arden Ceramide, Prevage, Eight Hour, SUPERSTART, Visible Difference, and Skin Illuminating brands; and fragrances under the Elizabeth Arden White Tea, Elizabeth Arden Red Door, Elizabeth Arden 5th Avenue, and Elizabeth Arden Green Tea brands. The company's Portfolio segment offers color cosmetics under the Almay and SinfulColors brands; men's grooming products under the American Crew brand; nail polishes, gel nail color, and nail enhancements under the CND brand; nail care products under the Cutex brand; anti-perspirant deodorants under the Mitchum brand; hair care products under the Creme of Nature; and hair color line under the Llongueras brand. Its Fragrances segment develops, markets, and distributes owned and licensed fragrances, as well as distributes prestige fragrance brands owned by third parties. This segment offers its products under the Juicy Couture, John Varvatos, AllSaints, Britney Spears, Elizabeth Taylor, Christina Aguilera, Jennifer Aniston, Mariah Carey, Curve, Giorgio Beverly Hills, Ed Hardy, Charlie, Lucky Brand, Alfred Sung, Halston, Geoffrey Beene, and White Diamonds brands. It sells its products through sales force, sales representatives, independent distributors, mass and prestige retail, e-commerce sites, department stores, and specialty cosmetics stores, as well as licenses its Revlon and other trademarks to the manufacturers of complementary beauty-related products and accessories. Revlon, Inc. was founded in 1932 and is based in New York, New York. On June 15, 2022, Revlon, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full REVRQ Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this REVRQ vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REVRQ vs SCHDREVRQ vs JEPIREVRQ vs OREVRQ vs KOREVRQ vs MAINREVRQ vs JNJREVRQ vs MRKREVRQ vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.